title: [Evaluation of proposed criteria of disk susceptibility testing for tosufloxacin and lomefloxacin in NCCLS guidelines and WHO standards].
abstract: Disk diffusion zone diameter breakpoint criteria for Tosufloxacin and Lomefloxacin were tentatively established by correlating MICs with 1-, 5- and 10 micrograms of Tosufloxacin disk inhibitory zone diameters and with 10 micrograms of Lomefloxacin disk of those to 418 clinical isolates representing 32 species. We recommend 5 micrograms disks for Tosufloxacin with the following breakpoints: Susceptible (MIC, less than or equal to 0.5 microgram/ml), greater than or equal to 22 mm; intermediate, 17 to 21 mm; and resistant (MIC, greater than or equal to 2.0 micrograms/ml), less than or equal to 16 mm. We recommend 10 micrograms disks for Lomefloxacin with the following breakpoints: Susceptible (MIC, less than or equal to 2.0 micrograms/ml), greater than or equal to 21 mm; intermediate, 16 to 20 mm; and resistant (MIC, greater than or equal to 8.0 micrograms/ml), less than or equal to 15 mm. Using these criteria for Tosufloxacin and Lomefloxacin, the occurrence rate of major errors in judging susceptibility and resistance was 0.48%.
authors.affiliation: Department of Clinical Pathology, Tenri Hospital.
authors.forename: M
authors.initials: M
authors.lastname: Aihara
authors.forename: T
authors.initials: T
authors.lastname: Oguri
authors.forename: H
authors.initials: H
authors.lastname: Kanno
authors.forename: S
authors.initials: S
authors.lastname: Kubo
authors.forename: M
authors.initials: M
authors.lastname: Honda
authors.forename: K
authors.initials: K
authors.lastname: Satoh
authors.forename: Y
authors.initials: Y
authors.lastname: Daimon
authors.forename: K
authors.initials: K
authors.lastname: Yamanaka
authors.forename: K
authors.initials: K
authors.lastname: Sugawara
authors.forename: T
authors.initials: T
authors.lastname: Furuta
mesh_terms: D000890:Anti-Infective Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects / Q000254:growth & development; D024841:Fluoroquinolones; D008826:Microbial Sensitivity Tests / Q000379:methods / Q000592:standards; D009287:Naphthyridines / Q000494:pharmacology*; D009938:Organizations; D015363:Quinolones / Q000494:pharmacology*; D014481:United States; D014944:World Health Organization
chemical_list: D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; D015363:Quinolones; C055185:tosufloxacin; C053091:lomefloxacin